EA201992147A1 - Ингибиторы тирозинкиназы брутона - Google Patents

Ингибиторы тирозинкиназы брутона

Info

Publication number
EA201992147A1
EA201992147A1 EA201992147A EA201992147A EA201992147A1 EA 201992147 A1 EA201992147 A1 EA 201992147A1 EA 201992147 A EA201992147 A EA 201992147A EA 201992147 A EA201992147 A EA 201992147A EA 201992147 A1 EA201992147 A1 EA 201992147A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bruton
inhibitors
tyrosinkinase
tyrosinkinase inhibitors
btk
Prior art date
Application number
EA201992147A
Other languages
English (en)
Russian (ru)
Inventor
Ксибин Лиао
Джиа Ли
Джижиан Лю
Юубо Жоу
Анхуи Гао
Original Assignee
Сужоу Байджибугонг Фрамасьютикал Текнолоджи Ко.Лтд
Ксибин Лиао
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сужоу Байджибугонг Фрамасьютикал Текнолоджи Ко.Лтд, Ксибин Лиао filed Critical Сужоу Байджибугонг Фрамасьютикал Текнолоджи Ко.Лтд
Publication of EA201992147A1 publication Critical patent/EA201992147A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201992147A 2017-03-22 2018-03-21 Ингибиторы тирозинкиназы брутона EA201992147A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762474686P 2017-03-22 2017-03-22
PCT/US2018/023455 WO2018175512A1 (en) 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201992147A1 true EA201992147A1 (ru) 2020-02-20

Family

ID=63585694

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992147A EA201992147A1 (ru) 2017-03-22 2018-03-21 Ингибиторы тирозинкиназы брутона

Country Status (12)

Country Link
US (3) US11554118B2 (enExample)
EP (1) EP3601264A4 (enExample)
JP (1) JP7219902B2 (enExample)
KR (1) KR102627756B1 (enExample)
CN (1) CN110494433B (enExample)
AU (1) AU2018237123B2 (enExample)
CA (1) CA3055602A1 (enExample)
EA (1) EA201992147A1 (enExample)
IL (1) IL269152B2 (enExample)
MX (1) MX2019011116A (enExample)
WO (1) WO2018175512A1 (enExample)
ZA (1) ZA201906887B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018237123B2 (en) * 2017-03-22 2022-08-04 Xibin Liao Bruton's tyrosine kinase inhibitors
KR20210136995A (ko) * 2019-01-18 2021-11-17 시빈 리아오 브루톤 티로신 키나아제 억제제
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
EP3966204B1 (en) * 2019-05-10 2024-11-27 Henan Zhiwei Biomedicine Co., Ltd. Substituted 1-amino-1h-imidazole-5-carboxamide as bruton's tyrosine kinase inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111471048B (zh) * 2020-04-30 2021-06-15 成都海博为药业有限公司 一种具有含氮桥环、螺环或并环结构的化合物及其用途
CN115073468B (zh) * 2021-03-15 2023-12-22 药雅科技(上海)有限公司 咪唑并吡嗪类btk抑制剂的制备及用途
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
JP2007504220A (ja) * 2003-09-03 2007-03-01 ガラパゴス・エヌブイ イミダゾ［１，５−ａ］ピリジン又はイミダゾ［１，５−ａ］ピペリジン誘導体および５ＨＴ２Ａ受容体関連障害に対する薬剤の製造のためのその使用
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
ES2673973T3 (es) * 2006-09-22 2018-06-26 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
CA2681756C (en) 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2009143051A1 (en) * 2008-05-19 2009-11-26 Osi Pharmaceuticals, Inc. Substituted imidazopyr-and imidazotri-azines
US8658794B2 (en) * 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
EP2691392A1 (en) * 2011-03-31 2014-02-05 EMBLEM Technology Transfer GmbH Imidazo [1,2-a]pyridine compounds for use in therapy
GB2513821A (en) * 2011-06-28 2014-11-12 Andrew Levine Speech-to-text conversion
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CA2841887A1 (en) * 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
HRP20190135T1 (hr) 2011-07-19 2019-03-22 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-yl-benzamidi i 4-imidazotriazin-1-yl-benzamidi kao inhibitori btk
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
WO2013113097A1 (en) 2012-01-31 2013-08-08 Beta Pharma Canada Inc. Cyclic molecules as bruton's tyrosine kinase inhibitors
WO2014114185A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014113942A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
CA2921880A1 (en) * 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016106623A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
CN106478633A (zh) * 2015-08-27 2017-03-08 正大天晴药业集团股份有限公司 一类布鲁顿酪氨酸激酶抑制剂
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
CN108602827B (zh) * 2015-11-06 2021-08-20 安塞塔制药公司 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂
JP6972002B2 (ja) 2016-03-11 2021-11-24 エンジェル・ファーマシューティカル・カンパニー・リミテッド ブルトン型チロシンキナーゼを調節する化合物及び方法
CA3032795C (en) * 2016-06-30 2021-06-22 Yubin LV Imidazopyridinamine phenyl derivative and use thereof
WO2018033091A1 (zh) * 2016-08-17 2018-02-22 深圳市塔吉瑞生物医药有限公司 用于抑制酪氨酸激酶活性的稠合双环类化合物
AU2018237123B2 (en) * 2017-03-22 2022-08-04 Xibin Liao Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
IL269152A (en) 2019-11-28
US11554118B2 (en) 2023-01-17
IL269152B2 (en) 2023-11-01
US20190275037A1 (en) 2019-09-12
CA3055602A1 (en) 2018-09-27
IL269152B1 (en) 2023-07-01
ZA201906887B (en) 2022-03-30
CN110494433B (zh) 2023-03-17
KR20190133199A (ko) 2019-12-02
EP3601264A1 (en) 2020-02-05
CN110494433A (zh) 2019-11-22
WO2018175512A1 (en) 2018-09-27
JP2020511547A (ja) 2020-04-16
KR102627756B1 (ko) 2024-01-23
US10933063B2 (en) 2021-03-02
US20210107903A1 (en) 2021-04-15
AU2018237123B2 (en) 2022-08-04
BR112019019588A2 (pt) 2020-04-22
US11974999B2 (en) 2024-05-07
EP3601264A4 (en) 2021-03-24
MX2019011116A (es) 2020-02-05
AU2018237123A1 (en) 2019-10-10
JP7219902B2 (ja) 2023-02-09
US20210121458A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
PH12020500655A1 (en) Compounds
CL2019000992A1 (es) Conjugados de pirrolobenzodiazepina.
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
CY1123263T1 (el) Πολυκυκλικες ενωσεις ως αναστολεις κινασης τυροσινης bruton
EA201790271A1 (ru) Ингибиторы гликозидазы
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MY203303A (en) Compounds
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
MX2018008362A (es) Derivados de quinolin-2-ona.
LT3609886T (lt) Benzoazepino analogai kaip brutono tirozinkinazės inhibitoriai
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
MA52629A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
EA201992259A1 (ru) Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.